Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.86 |
| ▸ | MEN1 | O00255 | 6/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.86 |
| ▸ | MAOA | P21397 | 3/20 | 0.86 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.86 |
| ▸ | RECQL | P46063 | 2/20 | 0.86 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.86 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.86 |
| ▸ | TTR | P02766 | 1/20 | 0.86 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.86 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purpurin SCHEMBL29429206 | 0.93 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL29539242 | 0.93 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL33871 | 0.93 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL4970376 | 0.91 | MEN1 (0.96) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL15205999 | 0.91 | MEN1 (0.96) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL9856657 | 0.91 | MEN1 (0.96) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL18840047 | 0.91 | MEN1 (0.96) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL10574533 | 0.91 | MEN1 (0.96) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL10571410 | 0.88 | MEN1 (0.83) | MAPTMEN1KMT2AALDH1A1MAOA | |
| Purpurin SCHEMBL11811844 | 0.84 | MEN1 (0.83) | MAPTMEN1KMT2AALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC | 2022-11-17 | — | — | US | disclosed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20100242139-A1 | XENOHORMESIS BASED COMPOSITIONS AND METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | MAPT 3926/4885MEN1 1711/4885KMT2A 4742/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | MAPT 2118/4885MEN1 593/4885KMT2A 3932/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | MAPT 3552/4885MEN1 1906/4885KMT2A 4414/4885 |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | PRKG2, PRKG1, CIT | MAPT 2118/4885MEN1 593/4885KMT2A 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.